Human Natural Killer cell. (National Institute of Allergy and Infectious Diseases Image)The news: Modulus Therapeutics, a Seattle-based cellular therapy company spun out of the Allen Institute of Artificial Intelligence (AI2) Incubator, has sold its cell therapy platform assets to the Boston biotech company Ginkgo Bioworks. The companies did not disclose the terms of the acquisition. An article by Fierce Biotech noted that Ginkgo’s business development team has snapped up a string of companies and assets in ...